Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 18/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 17/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 17/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21612007 | 0.89 | NOTUM (0.51) | RXRAGRIN1GRIN2BNOTUMCYP3A4 | |
| SCHEMBL21614754 | 0.82 | NOTUM (0.50) | RXRAGRIN1GRIN2BNOTUM | |
| SCHEMBL21614706 | 0.81 | CYP3A4 (0.46) | RXRAGRIN1GRIN2BNOTUMCYP3A4 | |
| SCHEMBL21611954 | 0.81 | RXRA (0.48) | RXRAGRIN1GRIN2BNOTUMCYP3A4 | |
| SCHEMBL21614693 | 0.81 | CYP3A4 (0.51) | RXRAGRIN1GRIN2BCYP3A4CYP2C19 | |
| SCHEMBL21614668 | 0.79 | CYP3A4 (0.67) | RXRAGRIN1GRIN2BCYP3A4CYP2C19 | |
| SCHEMBL21614685 | 0.79 | NOTUM (0.51) | RXRAGRIN1GRIN2BNOTUMCYP3A4 | |
| SCHEMBL21614686 | 0.76 | HDAC8 (0.49) | RXRAGRIN1GRIN2BCYP3A4CYP2C19 | |
| SCHEMBL21612054 | 0.72 | CYP3A4 (0.65) | RXRAGRIN1GRIN2BCYP3A4CYP2C19 | |
| SCHEMBL21614682 | 0.71 | CYP2C19 (0.64) | RXRAGRIN1GRIN2BNOTUMCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210353606-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-11-18 | — | — | US | disclosed |
| EP-3818045-A1 | PQSR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020007938-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-01-09 | — | — | WO | disclosed |
| WO-2020007938-A1 | PqsR INVERSE AGONISTS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210353606-A1 | PqsR INVERSE AGONISTS | QRFPR, P2RY11, QARS1 | RXRA 610/4885GRIN1 1447/4885GRIN2B 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.